Knight Therapeutics Inc.

TSX:GUD Voorraadrapport

Marktkapitalisatie: CA$525.2m

Knight Therapeutics Beheer

Beheer criteriumcontroles 3/4

De CEO Knight Therapeutics is Samira Sakhia, benoemd in Aug2016, heeft een ambtstermijn van 8.25 jaar. De totale jaarlijkse vergoeding van { bedraagt CA$ 1.33M, bestaande uit 38.6% salaris en 61.4% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.28% van de aandelen van het bedrijf, ter waarde CA$ 1.45M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.4 jaar en 8.3 jaar.

Belangrijke informatie

Samira Sakhia

Algemeen directeur

CA$1.3m

Totale compensatie

Percentage CEO-salaris38.6%
Dienstverband CEO8.3yrs
Eigendom CEO0.3%
Management gemiddelde ambtstermijn3.4yrs
Gemiddelde ambtstermijn bestuur8.3yrs

Recente managementupdates

Recent updates

Knight Therapeutics Inc. (TSE:GUD) Just Reported Earnings, And Analysts Cut Their Target Price

Nov 09
Knight Therapeutics Inc. (TSE:GUD) Just Reported Earnings, And Analysts Cut Their Target Price

Does Knight Therapeutics (TSE:GUD) Have A Healthy Balance Sheet?

May 28
Does Knight Therapeutics (TSE:GUD) Have A Healthy Balance Sheet?

Shareholders May Not Be So Generous With Knight Therapeutics Inc.'s (TSE:GUD) CEO Compensation And Here's Why

May 07
Shareholders May Not Be So Generous With Knight Therapeutics Inc.'s (TSE:GUD) CEO Compensation And Here's Why

Calculating The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)

Apr 07
Calculating The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)

Read This Before Selling Knight Therapeutics Inc. (TSE:GUD) Shares

Mar 20
Read This Before Selling Knight Therapeutics Inc. (TSE:GUD) Shares

If You Had Bought Knight Therapeutics' (TSE:GUD) Shares Three Years Ago You Would Be Down 34%

Mar 02
If You Had Bought Knight Therapeutics' (TSE:GUD) Shares Three Years Ago You Would Be Down 34%

Knight Therapeutics (TSE:GUD) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Feb 03
Knight Therapeutics (TSE:GUD) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Knight Therapeutics's (TSE:GUD) Earnings Are Growing But Is There More To The Story?

Jan 19
Knight Therapeutics's (TSE:GUD) Earnings Are Growing But Is There More To The Story?

What Type Of Shareholders Own The Most Number of Knight Therapeutics Inc. (TSE:GUD) Shares?

Jan 04
What Type Of Shareholders Own The Most Number of Knight Therapeutics Inc. (TSE:GUD) Shares?

A Look At The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)

Dec 20
A Look At The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)

The Founder of Knight Therapeutics Inc. (TSE:GUD), Jonathan Goodman, Just Bought A Few More Shares

Dec 07
The Founder of Knight Therapeutics Inc. (TSE:GUD), Jonathan Goodman, Just Bought A Few More Shares

What Type Of Returns Would Knight Therapeutics'(TSE:GUD) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Dec 02
What Type Of Returns Would Knight Therapeutics'(TSE:GUD) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Analyse CEO-vergoeding

Hoe is Samira Sakhia's beloning veranderd ten opzichte van Knight Therapeutics's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

-CA$31m

Jun 30 2024n/an/a

-CA$21m

Mar 31 2024n/an/a

-CA$17m

Dec 31 2023CA$1mCA$514k

-CA$17m

Sep 30 2023n/an/a

-CA$8m

Jun 30 2023n/an/a

-CA$16m

Mar 31 2023n/an/a

-CA$15m

Dec 31 2022CA$1mCA$468k

-CA$30m

Sep 30 2022n/an/a

-CA$23m

Jun 30 2022n/an/a

-CA$33m

Mar 31 2022n/an/a

-CA$7m

Dec 31 2021CA$1mCA$401k

CA$16m

Sep 30 2021n/an/a

CA$32m

Jun 30 2021n/an/a

CA$59m

Mar 31 2021n/an/a

CA$47m

Dec 31 2020CA$688kCA$298k

CA$42m

Sep 30 2020n/an/a

CA$27m

Jun 30 2020n/an/a

CA$6m

Mar 31 2020n/an/a

CA$8m

Dec 31 2019CA$987kCA$287k

CA$15m

Sep 30 2019n/an/a

CA$21m

Jun 30 2019n/an/a

CA$37m

Mar 31 2019n/an/a

CA$22m

Dec 31 2018CA$787kCA$267k

CA$24m

Sep 30 2018n/an/a

CA$31m

Jun 30 2018n/an/a

CA$22m

Mar 31 2018n/an/a

CA$18m

Dec 31 2017CA$438kCA$263k

CA$17m

Compensatie versus markt: De totale vergoeding ($USD 953.52K ) Samira } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de Canadian markt ($USD 1.18M ).

Compensatie versus inkomsten: De vergoeding van Samira is gestegen terwijl het bedrijf verliesgevend is.

CEO

Samira Sakhia (56 yo)

8.3yrs

Tenure

CA$1,331,900

Compensatie

Ms. Samira Sakhia, MBA, BCom, CPA, CA, has been the President at Knight Therapeutics Inc. since August 31, 2016 and served as its Chief Financial Officer since October 10, 2017 until March 30, 2020. She ha...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Jonathan Goodman
Executive Chairman11.8yrsCA$490.55k0.95%
CA$ 5.0m
Samira Sakhia
President8.3yrsCA$1.33m0.28%
CA$ 1.4m
Arvind Utchanah
Chief Financial Officer4.7yrsCA$869.82k0.042%
CA$ 218.9k
Amal Khouri
Chief Business Officer3.7yrsCA$839.55k0.16%
CA$ 818.8k
Stephani Saverio
Vice President of Business Development3.6yrsCA$629.57kgeen gegevens
Leopoldo Bosano
Vice-President of Manufacturing & Operations2.7yrsgeen gegevensgeen gegevens
Henrique Dias
Global Director of Marketing1.8yrsgeen gegevens0.0026%
CA$ 13.5k
Susan Emblem
Global Vice President of Human Resources3.3yrsgeen gegevens0.020%
CA$ 107.0k
Jeff Martens
Global Vice President of Commercial4.1yrsCA$534.15kgeen gegevens
Melanie Groleau
Global Vice President of Medical & Clinicalless than a yeargeen gegevens0.0030%
CA$ 15.9k

3.4yrs

Gemiddelde duur

Ervaren management: Het managementteam van GUD wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.4 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Jonathan Goodman
Executive Chairman11.8yrsCA$490.55k0.95%
CA$ 5.0m
Samira Sakhia
President8.3yrsCA$1.33m0.28%
CA$ 1.4m
James Gale
Independent Lead Director11.8yrsCA$155.00k0.052%
CA$ 273.0k
Robert Lande
Independent Director10.8yrsCA$127.50k0.24%
CA$ 1.3m
Nicolas Sujoy
Independent Director4.4yrsCA$132.43k0.012%
CA$ 61.5k
Janice Murray
Independent Director4.4yrsCA$122.50k0.0084%
CA$ 44.3k
Michael Tremblay
Independent Director5.5yrsCA$115.00k0.0020%
CA$ 10.4k

8.3yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van GUD wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.3 jaar).